NCT06999343 (AMICO) is a Phase 3 clinical trial of Metformin 850Mg Tab in COPD, sponsored by Fundación Instituto de Investigación Sanitaria de Navarra.

Who is sponsoring NCT06999343?

NCT06999343 is sponsored by Fundación Instituto de Investigación Sanitaria de Navarra.

What drugs are being tested in NCT06999343?

Interventions in NCT06999343: Metformin 850Mg Tab, Placebo.

Is NCT06999343 still recruiting?

NCT06999343 is currently not yet recruiting. Last updated 31 May 2025.

Last reviewed 2025-05-31 · How we verify

NCT06999343: AMICO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploring the Anti-ageing Effects of Metformin in COPD

Not yet recruiting Phase 3 Last updated 31 May 2025

What this trial tests

Phase 3 trial testing Metformin 850Mg Tab in COPD in 212 participants. Not yet recruiting.

Timeline

1 September 2025

Primary endpoint
1 May 2029

1 September 2029

Quick facts

Lead sponsor	Fundación Instituto de Investigación Sanitaria de Navarra
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	212
Start date	1 September 2025
Primary completion	1 May 2029
Estimated completion	1 September 2029

Drugs / interventions tested

Metformin 850Mg Tab — full drug profile →
Placebo

Conditions studied

COPD — all drugs for COPD →

Sponsor

Fundación Instituto de Investigación Sanitaria de Navarra — full company profile →

Who can join

Adults 40 to 75, any sex, with COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, multicentre, double-blind, placebo-controlled, randomised, prospective clinical trial comparing the effect of metformin 850 mg twice daily with placebo in COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1. Main objective: To compare the change in FEV1 at 3 years follow-up in patients receiving metformin versus placebo. Participants will take metformin (850mg) or placebo twice daily for 3 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COPD

Currently open trials in the same condition.

NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06999343 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Instituto de Investigación Sanitaria de Navarra
Last refreshed: 31 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06999343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing